Noxopharm Announces NYX-104 Delivers Key Proof-of-Concept in Stroke Animal Model

Noxopharm and its US subsidiary, Nyrada Inc, are pleased to announce jointly that the experimental drug, NYX-104, has cleared a critical step in its development as a neuroprotective drug.

Data released today at the 12th Cerebral Vascular Biology International Conference being held in Melbourne shows that NYX-104 was able to provide a significant level of neuroprotection in a mouse model of human stroke.

Any injury to the brain (e.g. stroke, concussion, head trauma, severe epilepsy, concussive noise) is associated with 2 phases of brain cell death. The first phase is immediate and involves the death of brain cells directly injured by the trauma. The second phase extends over days and weeks and involves a wave of cell death that radiates out from the original site of injury, potentially resulting finally in an area of brain death many times greater than the original injury. This second phase is known as excitotoxicity. The extent of excitotoxicity can mean the difference between making a full recovery from stroke with minimal rehabilitation, to being left months later with significant functional impairment despite lengthy rehabilitation.

Noxopharm announced recently (3 November 2017) that a collaboration between NOX and the University of NSW (Sydney) had identified NYX-104 as a potential drug candidate to treat excitotoxicity. That report was based on an ability to inhibit the excitotoxicity reaction in vitro. The data reported on today confirms that this inhibitory effect carried through in vivo, confirming the ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Operational Office: Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia Board of Directors Mr Peter Marks Chairman Non-Executive Director Dr Graham Kelly Chief Executive Officer Managing Director Dr Ian Dixon Non-Executive Director ability of the drug to cross the blood-brain barrier, and clearing the way for Nyrada to bring NYX-104 through into the clinic.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s